The cardiovascular continuum refined: A hypothesis

References

• Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin–angiotensin–aldosterone system. J Am Soc Nephrol. 2006;17:S36–S43.
   Web of Science ®Google Scholar
• Bohm M, Reil JC, Danchin N, Thoenes M, Bramlage P, Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: Data from i-search. J Hypertens. 2008;26:18–25.
   Google Scholar
• Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens. 2003;21: 1213–1220.
   PubMed Web of Science ®Google Scholar
• Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: Association with incident coronary heart disease and death. Hypertension. 2005;46:33–37.
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, . Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198–202.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of c-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369.
   PubMed Web of Science ®Google Scholar
• James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, . N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275–281.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, . Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195–207.
   PubMed Web of Science ®Google Scholar
• Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110: 1103–1107.
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, . BNP-guided vs symptom-guided heart failure therapy: The trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA. 2009;301:383–392.
   PubMed Web of Science ®Google Scholar
• Wilson PW; CDC; AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation. 2004;110:e568–e571.
   Google Scholar
• Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, . Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–2639.
   PubMed Web of Science ®Google Scholar
• Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, . Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006;48:1733–1741.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA. 1994;271:840–844.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, . Angiotensin ii receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005;45: 712–719.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, . Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:705–711.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA; VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403–411.
   PubMed Web of Science ®Google Scholar
• Connolly S, Yusuf S, Budaj A, Camm J, Chrolavicius S, Commerford PJ, . Rationale and design of active: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J. 2006;151:1187–1193; results presented at ESC 2009.
   PubMed Web of Science ®Google Scholar
• Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, . Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J. 2008;29:339–347.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, . Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The Charm-preserved trial. Lancet. 2003;362: 777–781.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345.
   PubMed Web of Science ®Google Scholar
• Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, . Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359:2456–2467.
   PubMed Web of Science ®Google Scholar